雷康璠, 吴松, 张文轩. 抗鲍曼不动杆菌药物研究进展J. 药学学报, 2023, 58(12): 3583-3598. DOI: 10.16438/j.0513-4870.2023-1108
引用本文: 雷康璠, 吴松, 张文轩. 抗鲍曼不动杆菌药物研究进展J. 药学学报, 2023, 58(12): 3583-3598. DOI: 10.16438/j.0513-4870.2023-1108
LEI Kang-fan, WU Song, ZHANG Wen-xuan. Research progress of anti-Acinetobacter baumannii drugJ. Acta Pharmaceutica Sinica, 2023, 58(12): 3583-3598. DOI: 10.16438/j.0513-4870.2023-1108
Citation: LEI Kang-fan, WU Song, ZHANG Wen-xuan. Research progress of anti-Acinetobacter baumannii drugJ. Acta Pharmaceutica Sinica, 2023, 58(12): 3583-3598. DOI: 10.16438/j.0513-4870.2023-1108

抗鲍曼不动杆菌药物研究进展

Research progress of anti-Acinetobacter baumannii drug

  • 摘要: 鲍曼不动杆菌具有耐药性强、致死率高、难以治疗的特点。现有的抗鲍曼不动杆菌药物的耐药现象不断出现, 临床可用药物相对较少, 因此对于新型抗鲍曼不动杆菌药物的研发已迫在眉睫。本文综述了临床使用的和在研的抗鲍曼不动杆菌药物研究进展, 以期对抗鲍曼不动杆菌药物的研发提供帮助。

     

    Abstract: Compared with other drug-resistant strains, Acinetobacter baumannii has the characteristics of serious drug resistance, high mortality and difficulty to treat. As the phenomena of resistance to existing anti-Acinetobacter baumannii drugs continuously occurs, the development of new anti-Acinetobacter baumannii drugs is urgent. This review introduces the clinical application and research progress of anti-Acinetobacter baumannii drugs, aiming to provide help for the research and development of anti-Acinetobacter baumannii drugs.

     

/

返回文章
返回